SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be participating in the SVB Leerink 11 th Annual Global Healthcare Conference.
Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virus Initial performance results show potentially significant quality, time, and cost advantages compared to traditional
Pfizer and Codex DNA agree to strategic, multiyear, early access research collaboration, leveraging Codex DNA’s novel enzymatic DNA synthesis (EDS) technology Pfizer’s successful development and commercialization of licensed products could result in milestone payments in excess of $100 million SAN